Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2025-07-01 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
关于回购股份进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Changchun High-tech Industry Group Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, prices, compliance with regulations, and references previous announcements about the repurchase plan. The document length is short (1348 characters) and it focuses on reporting the progress of a share buyback, not presenting full financial statements or detailed financial analysis. This fits the category of a Transaction in Own Shares (POS) filing, which covers company announcements about share repurchases or sales of own shares.
2025-07-01 Chinese
第十一届董事会第十次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of a board meeting resolution by Changchun High-tech Industry (Group) Co., Ltd. It details the convening of the 11th Board's 10th meeting, the unanimous approval of a proposal to authorize management to initiate preparations for an overseas issuance of H shares and listing on the Hong Kong Stock Exchange. The document includes procedural details about the meeting, voting results, and references to related disclosures. There are no financial statements or detailed financial data presented, nor is this a report or presentation. It is clearly an announcement of a board decision related to capital raising activities (H share issuance and listing). Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a full report or regulatory filing but a specific update on financing plans.
2025-07-01 Chinese
关于授权公司管理层启动公司境外发行股份（H股）并在香港联合交易所有限公司上市相关筹备工作的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (920 characters) regarding the authorization by the company's board to start preparatory work for an overseas issuance of H shares and listing on the Hong Kong Stock Exchange. It discusses the board meeting decision, regulatory requirements, and the uncertainty of the listing process. There are no financial statements or detailed financial data presented. The document serves as a notice of the company's intention and preparatory steps rather than a full report or detailed update on financing completion. Therefore, it fits best as a Capital/Financing Update (CAP) since it relates to company fundraising and capital structure changes in progress.
2025-07-01 Chinese
2024年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2024 annual equity distribution (dividend) plan of Changchun High-tech Industry (Group) Co., Ltd. It details the dividend amount per share, the total dividend payout, the record date, the ex-dividend date, and the method of dividend distribution. It also references the approval of the dividend plan at the 2024 annual shareholders meeting and adjustments related to share repurchases. The document is primarily focused on informing shareholders about the dividend payment details rather than presenting a full annual report or financial statements. The document length is about 3,074 characters, which is relatively short and consistent with a dividend announcement rather than a full report. Therefore, this document fits the category of a Notice of Dividend Amount (DIV).
2025-06-26 Chinese
关于子公司流感病毒裂解疫苗（BK-01佐剂）临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Changchun High-tech Industry Group Co., Ltd. regarding the approval of a clinical trial application for a subsidiary's influenza vaccine by the National Medical Products Administration. It contains no financial data, no mention of financial results, no detailed report or presentation, and is primarily a regulatory announcement about a clinical trial approval. The document length is short (1199 characters) and it is an announcement of an event rather than a report or detailed filing. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-06-19 Chinese
关于醋酸甲地孕酮口服混悬液（美适亚）药物临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Changchun High & New Technology Industries (Group) Co., Ltd. regarding the approval of a clinical trial application for a pharmaceutical product. It details the drug's basic information, clinical trial approval, and potential impact on the company. The document is short (1298 characters) and serves as an official announcement of a regulatory approval event rather than a detailed financial or management report. It does not contain financial statements, management discussion, or detailed regulatory filings but is a regulatory announcement about a clinical trial approval. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-06-13 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.